Zhang Li, Hao Chunfang, Wu Yansheng, Zhu Yuying, Ren Yulin, Tong Zhongsheng
Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China,
Department of Maxillofacial and Otorhinolaryngology Head and Neck Surgery, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
Onco Targets Ther. 2019 Mar 15;12:2023-2033. doi: 10.2147/OTT.S187835. eCollection 2019.
Microcalcification is a very important diagnostic information in breast cancer. The purpose of this study was to determine the relationship of clinicopathological features and prognosis of breast cancer with microcalcification and to detect biomarkers related to the possible mechanisms of microcalcifications.
All 529 subjects with microcalcifications were selected from patients who had been examined using breast mammography. The control group did not have detectable microcalcifications, and was matched in a ratio of 1:3. The clinicopathological factors, progression-free survival (PFS), and overall survival were evaluated by SPSS.
There was a significant difference in tumor size between the two groups, with larger tumors in the calcification group than the control group, and the proportion of patients in the calcification group with tumors of >5 cm was 20.4% vs 17.2% in the control group (=0.041). The proportion of patients with lymph node metastasis in the calcification group was higher than that of the control group (35% vs 27.9%, =0.027). The recurrence rate in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) patients with microcalcification was higher than that in the control group (=0.035 and 0.044). BMP-2 expression was higher in breast cancer tissues, especially in breast cancer tissues with microcalcifications. The recurrence rate in the BMP-2(+) group was higher than that in the BMP-2(-) group both in DCIS and IDC (=0.044 and 0.049). Microcalcifications and the positive expression of BMP-2 were independent factors affecting the PFS of the breast cancer patients.
Through the analysis of this study, it was found that the prognosis of the patients with microcalcification was relatively poor. BMP-2 was highly expressed in the breast cancer with microcalcification and was associated with poor prognosis.
微钙化是乳腺癌中非常重要的诊断信息。本研究的目的是确定乳腺癌微钙化与临床病理特征及预后的关系，并检测与微钙化可能机制相关的生物标志物。
选取529例经乳腺钼靶检查发现有微钙化的患者。对照组未检测到微钙化，按1:3的比例进行匹配。采用SPSS评估临床病理因素、无进展生存期（PFS）和总生存期。
两组肿瘤大小存在显著差异，钙化组肿瘤大于对照组，钙化组肿瘤>5 cm的患者比例为20.4%，而对照组为17.2%（P = 0.041）。钙化组患者淋巴结转移比例高于对照组（35%对27.9%，P = 0.027）。微钙化的导管原位癌（DCIS）和浸润性导管癌（IDC）患者的复发率高于对照组（P = 0.035和0.044）。骨形态发生蛋白-2（BMP-2）在乳腺癌组织中表达较高，尤其是在有微钙化的乳腺癌组织中。DCIS和IDC中，BMP-2（+）组的复发率均高于BMP-2（-）组（P = 0.044和0.049）。微钙化和BMP-2的阳性表达是影响乳腺癌患者PFS的独立因素。
通过本研究分析发现，微钙化患者预后相对较差。BMP-2在伴有微钙化的乳腺癌中高表达且与预后不良相关。
